GlassScriptPhysician profile
Priscilla M Borrego
NPI 1346231768
$17,208.33
in general payments reported to CMS, 2019-2025
25 companies · $3,381 in 2025
The $3,381 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,872 · 2020: $817 · 2021: $580 · 2022: $1,764 · 2023: $2,951 · 2024: $4,844 · 2025: $3,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,990 · Travel and Lodging: $1,110 · Education: $75.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,990.28 |
| Travel and Lodging | $1,109.77 |
| Education | $75.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,472.35 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $2,580.83 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $2,045.26 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,043.38 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $1,015.56 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Sunovion Pharmaceuticals INC. | $971.53 | 2019-2022 | |
| Allergan, INC. | $899.66 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $886.51 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $853.72 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $769.29 | 2019-2025 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $635.03 | 2024-2025 | Cobenfy |
| Indivior INC. | $476.77 | 2019-2024 | Perseris |
| Axsome Therapeutics, INC. | $454.54 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $322.63 | 2022-2025 | Loreev Xr, Citalopram, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $294.74 | 2019-2025 | Fanapt, Hetlioz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $178.52 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $88.57 | 2022-2024 | |
| Noven Therapeutics, LLC | $69.23 | 2024 | Secuado, Xelstrym |
| Viiv Healthcare Company | $28.67 | 2023 | Apretude |
| Tonix Medicines, INC. | $25.31 | 2025 | Tonmya |
| Idorsia Pharmaceuticals US INC | $20.94 | 2023 | Quviviq |
| Luye Pharma (USA) LTD. | $20.33 | 2025 | Erzofri Extended-Release |
| Emd Serono, INC. | $20.26 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.74 | 2020 | |
| Shire North American Group INC | $16.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Borrego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.